REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
REGENERON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$782.04−8.70 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $82.90B
- P/E (TTM)
- 19.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
24.9%−17.1 pts over 5 years
Net margin
31.4%−9.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1.0% | +5.6% | +11.0% | +13.3% | |
| Operating income | -10.3% | -8.9% | +0.0% | +11.1% | |
| Net income | +2.1% | +1.3% | +5.1% | +21.6% | |
| EPS, diluted | +8.2% | +2.8% | +6.3% | +22.3% | |
| Free cash flow | +11.3% | -2.7% | +15.3% | +20.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 22.1% | 31.8% | 14.9% | |
| Return on assets | 14.2% | 22.0% | 11.5% | |
| Current ratio | 2.56 | 3.63 | 4.13 | |
| Debt to equity | – | 0.18 | 0.06 | |
| Net debt to EBITDA | – | -0.06× | -0.27× | |
| Interest coverage | 184.8× | 62.9× | 81.7× | |
| Inventory turnover | 0.6× | – | – | |
| Capex to revenue | 10.5% | 7.2% | 6.3% | |
| Diluted shares | 116M | 115M | 109M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Regeneron Pharmaceuticals generated $26.09B from operations and spent $15.89B on capital expenditure, dividends and share buybacks. 22% of that went back into the business.
Generated
$26.09B
Used
$15.89B
Capital expenditure$3.51B22%Dividends$370.30M2%Share buybacks$12.01B76%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin31.4%
×Asset turnover0.37×
×Equity multiplier1.29×
=Return on equity, FY202514.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 31.4% | 0.37× | 1.29× | 14.9% |
| FY2024 | 31.1% | 0.40× | 1.28× | 16.0% |
| FY2023 | 30.1% | 0.42× | 1.28× | 16.3% |
| FY2022 | 35.6% | 0.45× | 1.32× | 20.9% |
| FY2021 | 50.2% | 0.75× | 1.43× | 54.2% |
| FY2020 | 41.3% | 0.53× | 1.45× | 31.8% |
| FY2019 | 32.3% | 0.49× | 1.34× | 21.3% |
| FY2018 | 47.5% | 0.50× | 1.38× | 32.8% |
| FY2017 | 20.4% | 0.75× | 1.49× | 22.6% |
| FY2016 | 18.4% | 0.77× | 1.55× | 22.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$4.50B
- Cash generatingOperating cash flow above zero$4.98B
- Return on assets improvedROA up on the prior year13.3% → 11.9%
- Earnings backed by cashOperating cash flow above net income$4.98B vs $4.50B
- Less leverageLong-term debt to assets fell5.3% → 4.9%
- Better liquidityCurrent ratio rose4.73 → 4.13
- No dilutionShare count did not rise115M → 109M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.43 → 0.38